On June 11, 2025, PDS Biotechnology (PDSB, Financial) received reiterated support from analyst Joseph Pantginis of HC Wainwright & Co. The analyst has maintained a 'Buy' rating for the stock, reflecting continued confidence in the company's potential.
The price target for PDS Biotechnology (PDSB, Financial) remains steady at $13.00, indicating no change from the prior valuation. This suggests that the analyst's outlook on the company's market performance and growth prospects have remained consistent.
Investors may note that the reiterated 'Buy' rating indicates a positive endorsement of PDSB's current strategies and potential future developments. The target price remains in USD and aligns with previous assessments, showing stability in the analyst's projections.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for PDS Biotechnology Corp (PDSB, Financial) is $7.50 with a high estimate of $13.00 and a low estimate of $4.50. The average target implies an upside of 346.43% from the current price of $1.68. More detailed estimate data can be found on the PDS Biotechnology Corp (PDSB) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, PDS Biotechnology Corp's (PDSB, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
